Aarhus University Seal / Aarhus Universitets segl

The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFα Treatment in Crohn's Disease

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFα Treatment in Crohn's Disease. / Mortensen, Joachim H; van Haaften, Wouter T; Karsdal, Morten A; Bay-Jensen, Anne-Christine; Olinga, Peter; Grønbæk, Henning; Hvas, Christian L; Manon-Jensen, Tina; Dijkstra, Gerard; Dige, Anders.

In: Journal of Clinical Gastroenterology, Vol. 55, No. 1, 01.2021, p. 59-66.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Mortensen, JH, van Haaften, WT, Karsdal, MA, Bay-Jensen, A-C, Olinga, P, Grønbæk, H, Hvas, CL, Manon-Jensen, T, Dijkstra, G & Dige, A 2021, 'The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFα Treatment in Crohn's Disease', Journal of Clinical Gastroenterology, vol. 55, no. 1, pp. 59-66. https://doi.org/10.1097/MCG.0000000000001341

APA

Mortensen, J. H., van Haaften, W. T., Karsdal, M. A., Bay-Jensen, A-C., Olinga, P., Grønbæk, H., Hvas, C. L., Manon-Jensen, T., Dijkstra, G., & Dige, A. (2021). The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFα Treatment in Crohn's Disease. Journal of Clinical Gastroenterology, 55(1), 59-66. https://doi.org/10.1097/MCG.0000000000001341

CBE

Mortensen JH, van Haaften WT, Karsdal MA, Bay-Jensen A-C, Olinga P, Grønbæk H, Hvas CL, Manon-Jensen T, Dijkstra G, Dige A. 2021. The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFα Treatment in Crohn's Disease. Journal of Clinical Gastroenterology. 55(1):59-66. https://doi.org/10.1097/MCG.0000000000001341

MLA

Vancouver

Mortensen JH, van Haaften WT, Karsdal MA, Bay-Jensen A-C, Olinga P, Grønbæk H et al. The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFα Treatment in Crohn's Disease. Journal of Clinical Gastroenterology. 2021 Jan;55(1):59-66. https://doi.org/10.1097/MCG.0000000000001341

Author

Mortensen, Joachim H ; van Haaften, Wouter T ; Karsdal, Morten A ; Bay-Jensen, Anne-Christine ; Olinga, Peter ; Grønbæk, Henning ; Hvas, Christian L ; Manon-Jensen, Tina ; Dijkstra, Gerard ; Dige, Anders. / The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFα Treatment in Crohn's Disease. In: Journal of Clinical Gastroenterology. 2021 ; Vol. 55, No. 1. pp. 59-66.

Bibtex

@article{f7773c5e92124d00b4b5a2b629195f6d,
title = "The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFα Treatment in Crohn's Disease",
abstract = "BACKGROUND: In Crohn's disease (CD), 10% to 40% of patients do not respond to anti-tumor necrosis factor-α (TNFα) treatment. Currently, there are no biomarkers with adequate sensitivity to separate responders from nonresponders at an early stage.AIM: The aim of this study was to investigated whether early changes in the VICM (citrullinated and matrix metalloproteinase-degraded vimentin) biomarker were associated with response to anti-TNFα treatment in patients with CD.METHODS: Serum VICM levels were measured by ELISA in 2 independent cohorts of CD patients (n=42) treated with anti-TNFα (infliximab or adalimumab). Response was determined by achieving clinical remission (Harvey Bradshaw Index<5).RESULTS: Compared with baseline, VICM serum levels were reduced by anti-TNFα in the infliximab cohort (week 6 and 14) and in the adalimumab cohort (week 8). VICM was lower in the responders compared with the nonresponders [infliximab: week 6, P<0.05; area under the curve (AUC)=0.90; adalimumab: week 1, P<0.01 (AUC=0.91), and week 8, P<0.05 (AUC=0.86)], and were able to predict response to treatment after 1 week of treatment with an odds ratio of 42.5.CONCLUSIONS: The VICM biomarker was time dependently reduced in CD patients responding to anti-TNFα treatment. We suggest that VICM may be used as a marker for monitoring early response to anti-TNFα in patients with CD.",
keywords = "Crohn's disease, anti-TNF, citrullinated vimentin, prediction of response, serological biomarkers",
author = "Mortensen, {Joachim H} and {van Haaften}, {Wouter T} and Karsdal, {Morten A} and Anne-Christine Bay-Jensen and Peter Olinga and Henning Gr{\o}nb{\ae}k and Hvas, {Christian L} and Tina Manon-Jensen and Gerard Dijkstra and Anders Dige",
year = "2021",
month = jan,
doi = "10.1097/MCG.0000000000001341",
language = "English",
volume = "55",
pages = "59--66",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "LIPPINCOTT WILLIAMS & WILKINS",
number = "1",

}

RIS

TY - JOUR

T1 - The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFα Treatment in Crohn's Disease

AU - Mortensen, Joachim H

AU - van Haaften, Wouter T

AU - Karsdal, Morten A

AU - Bay-Jensen, Anne-Christine

AU - Olinga, Peter

AU - Grønbæk, Henning

AU - Hvas, Christian L

AU - Manon-Jensen, Tina

AU - Dijkstra, Gerard

AU - Dige, Anders

PY - 2021/1

Y1 - 2021/1

N2 - BACKGROUND: In Crohn's disease (CD), 10% to 40% of patients do not respond to anti-tumor necrosis factor-α (TNFα) treatment. Currently, there are no biomarkers with adequate sensitivity to separate responders from nonresponders at an early stage.AIM: The aim of this study was to investigated whether early changes in the VICM (citrullinated and matrix metalloproteinase-degraded vimentin) biomarker were associated with response to anti-TNFα treatment in patients with CD.METHODS: Serum VICM levels were measured by ELISA in 2 independent cohorts of CD patients (n=42) treated with anti-TNFα (infliximab or adalimumab). Response was determined by achieving clinical remission (Harvey Bradshaw Index<5).RESULTS: Compared with baseline, VICM serum levels were reduced by anti-TNFα in the infliximab cohort (week 6 and 14) and in the adalimumab cohort (week 8). VICM was lower in the responders compared with the nonresponders [infliximab: week 6, P<0.05; area under the curve (AUC)=0.90; adalimumab: week 1, P<0.01 (AUC=0.91), and week 8, P<0.05 (AUC=0.86)], and were able to predict response to treatment after 1 week of treatment with an odds ratio of 42.5.CONCLUSIONS: The VICM biomarker was time dependently reduced in CD patients responding to anti-TNFα treatment. We suggest that VICM may be used as a marker for monitoring early response to anti-TNFα in patients with CD.

AB - BACKGROUND: In Crohn's disease (CD), 10% to 40% of patients do not respond to anti-tumor necrosis factor-α (TNFα) treatment. Currently, there are no biomarkers with adequate sensitivity to separate responders from nonresponders at an early stage.AIM: The aim of this study was to investigated whether early changes in the VICM (citrullinated and matrix metalloproteinase-degraded vimentin) biomarker were associated with response to anti-TNFα treatment in patients with CD.METHODS: Serum VICM levels were measured by ELISA in 2 independent cohorts of CD patients (n=42) treated with anti-TNFα (infliximab or adalimumab). Response was determined by achieving clinical remission (Harvey Bradshaw Index<5).RESULTS: Compared with baseline, VICM serum levels were reduced by anti-TNFα in the infliximab cohort (week 6 and 14) and in the adalimumab cohort (week 8). VICM was lower in the responders compared with the nonresponders [infliximab: week 6, P<0.05; area under the curve (AUC)=0.90; adalimumab: week 1, P<0.01 (AUC=0.91), and week 8, P<0.05 (AUC=0.86)], and were able to predict response to treatment after 1 week of treatment with an odds ratio of 42.5.CONCLUSIONS: The VICM biomarker was time dependently reduced in CD patients responding to anti-TNFα treatment. We suggest that VICM may be used as a marker for monitoring early response to anti-TNFα in patients with CD.

KW - Crohn's disease

KW - anti-TNF

KW - citrullinated vimentin

KW - prediction of response

KW - serological biomarkers

U2 - 10.1097/MCG.0000000000001341

DO - 10.1097/MCG.0000000000001341

M3 - Journal article

C2 - 32301833

VL - 55

SP - 59

EP - 66

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - 1

ER -